Literature DB >> 6089950

Effect of an oral serotonin antagonist, ketanserin, on plasma ACTH concentrations in Nelson's syndrome.

R W Prescott, W A Ratcliffe, P K Taylor.   

Abstract

A study was performed to see whether ketanserin, a serotonin antagonist, would reduce the raised concentrations of adrenocorticotrophic hormone (ACTH) in patients with Nelson's syndrome. Six patients who had undergone bilateral adrenalectomy for Cushing's disease and who had Nelson's syndrome were given ketanserin 40 mg twice daily and placebo, for at least two months each, in a double blind crossover study. Ketanserin had no effect on ACTH concentrations. In healthy people serotonin seems to have a stimulatory role in the regulation of ACTH secretion, and the effect of ketanserin in reducing the ACTH response to hypoglycaemia suggested that it might prove useful in Nelson's syndrome. These results show that it is not indicated in these patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6089950      PMCID: PMC1442912          DOI: 10.1136/bmj.289.6448.787

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  5 in total

1.  Sustained remission of Nelson's syndrome after stopping cyproheptadine treatment.

Authors:  N Aronin; D T Krieger
Journal:  N Engl J Med       Date:  1980-02-21       Impact factor: 91.245

2.  The effect of ketanserin, a specific serotonin antagonist on the PRL, GH, ACTH and cortisol responses to hypoglycaemia in normal subjects.

Authors:  R W Prescott; P Kendall-Taylor; D R Weightman; M J Watson; W A Ratcliffe
Journal:  Clin Endocrinol (Oxf)       Date:  1984-02       Impact factor: 3.478

3.  Corticotrophin releasing factor: responses in normal subjects and patients with disorders of the hypothalamus and pituitary.

Authors:  N Lytras; A Grossman; L Perry; S Tomlin; J A Wass; D H Coy; A V Schally; L H Rees; G M Besser
Journal:  Clin Endocrinol (Oxf)       Date:  1984-01       Impact factor: 3.478

4.  Serotonergic stimulation of adrenocorticotropin secretion in man.

Authors:  D A Lewis; B M Sherman
Journal:  J Clin Endocrinol Metab       Date:  1984-03       Impact factor: 5.958

5.  The evaluation of sodium valproate in the treatment of Nelson's syndrome.

Authors:  A Dornhorst; J S Jenkins; S W Lamberts; R R Abraham; V Wynn; U Beckford; B Gillham; M T Jones
Journal:  J Clin Endocrinol Metab       Date:  1983-05       Impact factor: 5.958

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.